Recent studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are showing significant outcomes in treating obesity and related second-type condition. Initial evidence suggest a unique mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/